Becton Dickinson and Company (BDX) - Stock & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0758871091

(NYSE:BDX Stock) Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey. Web URL: https://www.bd.com

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Becton Dickinson and Company (BDX) - Stock & Dividends

BDX Stock Overview

Market Cap in USD 69,068m
Sector Healthcare
Industry Medical Instruments & Supplies
GiC SubIndustry Health Care Equipment
TER 0.00%
IPO / Inception 1987-01-01

BDX Stock Ratings

Fundamental 1.16
Dividend 5.50
Growth 5y 1.72
Rel. Performance vs Sector -1.00
Analysts 4.24
Fair Price Total Ret. 258.81
Fair Price DCF 247.63

BDX Dividends

Yield 12m 1.50%
Yield on Cost 5y 1.61%
Dividends CAGR 5y 4.02%
Payout Consistency 79.2%

BDX Growth Ratios

Growth 12m 3.59%
Growth Correlation 12m -4%
Growth Correlation 3m 27%
CAGR 5y 1.46%
CAGR / Mean Drawdown 0.16
Sharpe Ratio 12m -0.08
Alpha vs SP500 12m -12.79
Beta vs SP500 5y weekly 0.52
CAPM 6.66%
Average Daily Range 2m 1.88%
Regime Oscillator 78.05
Volatility GJR Garch 1y 21.01%
Price / SMA 50 2.55%
Price / SMA 200 -2.81%
Current Volume 1623.8k
Average Volume 20d 1607.3k

External Links for BDX Stock

News
Wall Street JournalBenzingaYahoo Finance
Tweets
X (Twitter)Stocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of BDX stocks?
As of February 22, 2024, the stock is trading at USD 245.32 with a total of 1,623,811 shares traded.
Over the past week, the price has changed by +2.81%, over one month by +4.00%, over three months by +4.30% and over the past year by +3.98%.
Why is BDX stock down?
Check with which Index or Commodity BDX has the highest Correlation, do they have a common driver?
Review the Fundamentals to find weaknesses (Debt, low returns). Check the Performance of the Peer-Group to find out, if the entire sector is under pressure.
Period Return BDX Return S&P 500
1 Month 4.00% 2.85%
3 Months 4.30% 10.14%
12 Months 3.98% 26.48%
What is the forecast for BDX stock price target?
According to ValueRays Forecast Model, BDX Becton Dickinson and Company will be worth about 279.5 in February 2025. The stock is currently trading at 245.32. This means that the stock has a potential upside of +13.94%.
Issuer Forecast Upside
Wallstreet Target Price 278.5 13.5%
Analysts Target Price 301.2 22.8%
ValueRay Target Price 279.5 13.9%